4
Total investments
0
Early stage
0
Mid stage
1
Late stage
14y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
May 2014
HemoShear Therapeutics is a biotechnology company focused on discovering novel biological targets and developing drugs to treat children’s rare metabolic disorders. Our goal is to discover drugs that save the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for life. Our proprietary technology allows us to recapitulate diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates that we believe have high probabilities of clinical success.
HemoShear is markedly different from other biotechnology companies because of our proprietary human disease models and our ability to recreate and interpret complex human biology. We believe that no other company can match our ability to understand human hepatic, tumor, or vascular disease biology and translate those findings into discovery of safe and effective drug treatments.
We are passionate about understanding disease biology and driven to discover drug treatments that improve health outcomes and save lives. For more information, see www.hemoshear.com.
Experience · 4 entries
All (4)
Investments (4)
Board (2)
2014
Angel Investor
May 2014
HemoShear Therapeutics is a biotechnology company focused on discovering novel biological targets and developing drugs to treat children’s rare metabolic disorders. Our goal is to discover drugs that save the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for life. Our proprietary technology allows us to recapitulate diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates that we believe have high probabilities of clinical success.
HemoShear is markedly different from other biotechnology companies because of our proprietary human disease models and our ability to recreate and interpret complex human biology. We believe that no other company can match our ability to understand human hepatic, tumor, or vascular disease biology and translate those findings into discovery of safe and effective drug treatments.
We are passionate about understanding disease biology and driven to discover drug treatments that improve health outcomes and save lives. For more information, see www.hemoshear.com.
2013
H
Hemosonics
Angel Investor
Jan 2013
2012
L
Lewis and Clark Pharmaceuticals
Angel Investor and Board Member
Dec 2012
C
Computational Engineering International, Inc
Board Member
Oct 2012
Investment activity
2012–2014 · 4 investments
Recent (last 2 years)Earlier
